Overall Survival Data Confirm Benefit of Pembro in TNBC ...Middle East

News by : (Medscape) -
Neoadjuvant plus adjuvant immune therapy combined with chemotherapy reduced death by 34% in the KEYNOTE-522 trial. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Overall Survival Data Confirm Benefit of Pembro in TNBC )

Also on site :

Most Viewed News
جديد الاخبار